MedTrace Logo

Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes

NCT01545791 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1037

Last updated 2016-10-28

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of the study is to observe the safety of insulin detemir (Levemir®) in patients with type 1 and type 2 diabetes patients.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Interventions

DRUG

insulin detemir

Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01545791 on ClinicalTrials.gov